Wnt/β-Catenin Signaling in Osteoarthritis Pathogenesis

Osteoarthritis is a chronic joint disorder characterised by progressive cartilage degeneration, synovial inflammation and remodelling of subchondral bone. Central to these processes is the finely tuned activity of the canonical Wnt/β-catenin signalling cascade. Under physiological conditions, Wnt ligands bind to Frizzled and LRP co-receptors on the surface of chondrocytes to stabilise β-catenin, which then translocates to the nucleus to regulate genes involved in cartilage homeostasis. In osteoarthritis, aberrant activation of this pathway promotes chondrocyte hypertrophy, upregulation of matrix metalloproteinases and loss of cartilage extracellular matrix. Conversely, endogenous antagonists such as DKK1, FRZB and sclerostin normally restrain Wnt signalling to preserve cartilage integrity. Dysregulation may arise from mechanical overload, pro-inflammatory cytokines and epigenetic or post-transcriptional modifications, leading to a shift towards catabolic and hypertrophic programmes. Cross-talk with other pathways—including transforming growth factor-β, bone morphogenetic protein, Indian Hedgehog and NF-κB—further exacerbates tissue breakdown. Understanding the balance between Wnt-driven repair responses and maladaptive activation is crucial for the development of disease-modifying interventions.

Research from Nature Portfolio

Seminal work has identified the histone methyltransferase DOT1L as a guardian of cartilage health through negative regulation of Wnt signalling. Loss of DOT1L in preclinical models disrupts chondrocyte identity and precipitates osteoarthritic changes via unchecked activation of β-catenin. Mechanistically, DOT1L inhibits the deacetylase SIRT1, thereby preventing SIRT1-mediated enhancement of Wnt target genes. Restoration of DOT1L activity or inhibition of SIRT1 has been shown to attenuate cartilage degradation, highlighting an epigenetic axis that restrains Wnt-driven pathology and offering a promising route for therapeutic modulation.

Wnt/β-Catenin Signaling in Osteoarthritis Pathogenesis publication trend

The graph below shows the total number of articles in wnt/β-catenin signaling in osteoarthritis pathogenesis across all publications each year (not limited to Nature Index journals).

Technical terms

Wnt/β-catenin signalling: A molecular pathway in which Wnt proteins stabilise β-catenin, allowing it to enter the nucleus and control gene transcription.

Chondrocyte hypertrophy: Enlargement and terminal differentiation of cartilage cells, associated with increased degradative enzyme expression.

Extracellular matrix: The network of collagens, proteoglycans and glycoproteins that provides structural support and resilience to cartilage.

m6A modification: A reversible chemical mark on messenger RNA (N6-methyladenosine) that influences RNA stability and translation.

Histone methylation: The addition of methyl groups to histone proteins, an epigenetic mechanism that alters chromatin structure and gene expression.

References

1. WTAP-mediated m6A modification of FRZB triggers the inflammatory response via the Wnt signaling pathway in osteoarthritis. Experimental & Molecular Medicine (2024).
2. Signalling interaction between β‐catenin and other signalling molecules during osteoarthritis development. Cell Proliferation (2024).
3. Wnt signaling: a promising target for osteoarthritis therapy. Cell Communication and Signaling (2019).
4. DOT1L safeguards cartilage homeostasis and protects against osteoarthritis. Nature Communications (2017).